686 related articles for article (PubMed ID: 7518491)
1. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome.
Vaziri ND; Gonzales EC; Shayestehfar B; Barton CH
J Lab Clin Med; 1994 Jul; 124(1):118-24. PubMed ID: 7518491
[TBL] [Abstract][Full Text] [Related]
2. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
Cucuianu M; Knauer O; Roman S
Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
[TBL] [Abstract][Full Text] [Related]
3. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
4. [A coagulation of fibrinolytic study in children with nephrotic syndrome: evaluation of hypercoagulability by measuring with plasmin- alpha 2 plasmin inhibitor complex and FDP D-dimer].
Oikawa T; Muramatsu Y; Akashi S; Usui N
Nihon Jinzo Gakkai Shi; 1997 Mar; 39(2):144-9. PubMed ID: 9134831
[TBL] [Abstract][Full Text] [Related]
5. [Levels of tissue-type plasminogen activator and plasminogen activator inhibitor 1 in disseminated intravascular coagulation syndrome].
Fukao H; Yamamoto K; Matsuo O
Rinsho Byori; 1991 Jul; 39(7):720-6. PubMed ID: 1920864
[TBL] [Abstract][Full Text] [Related]
6. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer.
Nanninga PB; van Teunenbroek A; Veenhof CH; Büller HR; ten Cate JW
Thromb Haemost; 1990 Nov; 64(3):361-4. PubMed ID: 1710832
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolytic and protease inhibitory systems in spinal cord injured patients with end-stage renal disease.
Vaziri ND; Winer RL; Gonzales EV; Eltorai IM
J Am Paraplegia Soc; 1993 Jul; 16(3):149-52. PubMed ID: 7690062
[TBL] [Abstract][Full Text] [Related]
8. Laboratory evidence of hyperfibrinolysis in association with low plasminogen activator inhibitor type 1 activity.
Agren A; Wiman B; Schulman S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):657-60. PubMed ID: 17890953
[TBL] [Abstract][Full Text] [Related]
9. Nephrotic syndrome with renal vein thrombosis: pathogenetic importance of a plasmin inhibitor (alpha 2-antiplasmin).
Du XH; Glas-Greenwalt P; Kant KS; Allen CM; Hayes S; Pollak VE
Clin Nephrol; 1985 Oct; 24(4):186-91. PubMed ID: 3933871
[TBL] [Abstract][Full Text] [Related]
10. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
11. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
12. Factor XIII and its substrates, fibronectin, fibrinogen, and alpha 2-antiplasmin, in plasma and urine of patients with nephrosis.
Vaziri ND; Gonzales E; Barton CH; Chen HT; Nguyen Q; Arquilla M
J Lab Clin Med; 1991 Feb; 117(2):152-6. PubMed ID: 1993857
[TBL] [Abstract][Full Text] [Related]
13. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
[TBL] [Abstract][Full Text] [Related]
15. [Changes in coagulation and fibrinolytic factors observed during heparin-urokinase-pulse combined therapy for nephritis resistant to conventional treatment in children].
Koitabashi Y; Ikoma M; Shibawaka T; Yamaguchi Y; Mio H; Doi K; Meguro T; Yamada K
Nihon Jinzo Gakkai Shi; 1993 Oct; 35(10):1155-61. PubMed ID: 7505345
[TBL] [Abstract][Full Text] [Related]
16. [Coagulation and fibrinolysis proteins in nephrotic syndromes in children].
Loirat C; Pillion G; Schlegel N; Douenias R; Mathieu H
Arch Fr Pediatr; 1979 Nov; 36(9 Suppl):LVI-LXIII. PubMed ID: 539878
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo.
Levi M; Roem D; Kamp AM; de Boer JP; Hack CE; ten Cate JW
Thromb Haemost; 1993 Feb; 69(2):141-6. PubMed ID: 7681223
[TBL] [Abstract][Full Text] [Related]
18. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
19. Studies of fibrinolytic activity of uremic and longterm hemodialytic patients with special reference to fibrinolytic inhibitor.
Homma T; Ichikawa T
Biochem Exp Biol; 1979; 15(3):229-36. PubMed ID: 122165
[TBL] [Abstract][Full Text] [Related]
20. Plasma tetranectin levels and disease activity in patients with rheumatoid arthritis.
Kamper EF; Kopeikina LT; Koutsoukos V; Stavridis J
J Rheumatol; 1997 Feb; 24(2):262-8. PubMed ID: 9034981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
